Compare · MLYS vs NVO
MLYS vs NVO
Side-by-side comparison of Mineralys Therapeutics Inc. (MLYS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MLYS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 92.5x MLYS ($2.33B).
- MLYS has been more active in the news (15 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 10 for MLYS).
- Company
- Mineralys Therapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $2.33B
- $215.46B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 15
- 9
- Recent ratings
- 10
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MLYS
- Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
- Chief Commercial Officer Warren Eric exercised 7,437 shares at a strike of $13.24 and sold $193,189 worth of shares (7,437 units at $25.98) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Mineralys Therapeutics Inc.
- SEC Form 144 filed by Mineralys Therapeutics Inc.
- SEC Form 144 filed by Mineralys Therapeutics Inc.
- Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
- Chief Medical Officer Ferguson James J. Iii was granted 102,400 shares (SEC Form 4)
- SEC Form 3 filed by new insider Ferguson James J. Iii
- Chief Medical Officer Rodman David Malcom exercised 2,170 shares at a strike of $16.00 and sold $58,785 worth of shares (2,170 units at $27.09) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by Mineralys Therapeutics Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S